{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:47:50Z","timestamp":1777384070186,"version":"3.51.4"},"reference-count":27,"publisher":"Japan Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2015]]},"DOI":"10.1507\/endocrj.ej14-0152","type":"journal-article","created":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T01:10:51Z","timestamp":1412125851000},"page":"69-75","source":"Crossref","is-referenced-by-count":4,"title":["Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves&amp;rsquo; disease and type 1 diabetes mellitus: A case report"],"prefix":"10.1507","volume":"62","author":[{"given":"Akira","family":"Kurozumi","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Okada","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Arao","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Narisawa","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Torimoto","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunao","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. <i>Blood<\/i> 83: 435-445.","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nielsen CH, El Fassi D, Hasselbalch HC, Bendtzen K, Heged&uuml;s L (2007) B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves&rsquo; ophthalmopathy the latest addition to an expanding family. <i>Expert Opin Biol Ther<\/i> 7: 1061-1078.","DOI":"10.1517\/14712598.7.7.1061"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Edwards JC, Cambridge G (2006) B-cell targeting in rheumatoid arthritis and other autoimmune diseases. <i>Nat Rev Immunol<\/i> 6: 394-403.","DOI":"10.1038\/nri1838"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, et al. (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. <i>N Engl J Med<\/i> 361: 2143-2152.","DOI":"10.1056\/NEJMoa0904452"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tajiri J, Noguchi S (2004) Antithyroid drug-induced agranulocytosis: Special reference to normal white blood cell count agranulocytosis. <i>Thyroid<\/i> 14: 459-462.","DOI":"10.1089\/105072504323150787"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Nakamura H, Noh JY, Ttoh K, Fukata S, Miyauchi A, et al. (2007) Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves&rsquo; disease. <i>J Clin Endocrinol Metab<\/i> 92: 2157-2162.","DOI":"10.1210\/jc.2006-2135"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, et al. (1990) Antithyroid drugs and Graves&rsquo; disease: a prospective randomized evaluation of the efficacy of treatment duration. <i>J Clin Endocrinol Metab<\/i> 70: 675-679.","DOI":"10.1210\/jcem-70-3-675"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Garc&iacute;a-Mayor RV, P&aacute;ramo C, Luna Cano R, P&eacute;rez Mendez LF, Galofr&eacute; JC, et al. (1992) Antithyroid drug and Graves&rsquo; hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. <i>J Endocrinol Invest<\/i> 15: 815-820.","DOI":"10.1007\/BF03348811"},{"key":"9","unstructured":"9. Weetman AP, Pickerill AP, Watson P, Chatterjee VK, Edwards OM (1994) Treatment of Graves&rsquo; disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. <i>Q J Med <\/i>87: 337-341."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, et al. (1999) Antithyroid drugs and Graves&rsquo; disease--prospective randomized assessment of long-term treatment. <i>Clin Endocrinol (Oxf)<\/i> 50: 127-132.","DOI":"10.1046\/j.1365-2265.1999.00629.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Mashio Y, Beniko M, Matsuda A, Koizumi S, Matsuya K, et al. (1997) Treatment of hyperthyroidism with a small single daily dose of methimazole: a prospective long-term follow-up study. <i>Endocr J<\/i> 44: 553-558.","DOI":"10.1507\/endocrj.44.553"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Takamatsu J, Kuma K, Mozai T (1986) Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves&rsquo; disease. <i>J Clin Endocrinol Metab<\/i> 62: 980-983.","DOI":"10.1210\/jcem-62-5-980"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Konishi T, Okamoto Y, Ueda M, Fukuda Y, Harusato I, et al. (2011) Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves&rsquo; disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. <i>Endocr J<\/i> 58: 95-100.","DOI":"10.1507\/endocrj.K10E-262"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, et al. (2013) Comparative effectiveness of therapies for Graves&rsquo; hyperthyroidism: a systematic review and network meta-analysis. <i>J Clin Endocrinol Metab <\/i>98: 3671-3677.","DOI":"10.1210\/jc.2013-1954"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Salvi M, Vannucchi G, Campi I, Curr&ograve; N, Dazzi D, et al. (2007) Treatment of Graves&rsquo; disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. <i>Eur J Endocrinol<\/i> 156: 33-40.","DOI":"10.1530\/eje.1.02325"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. El Fassi D, Nielsen CH, Hasselbalch HC, Heged&uuml;s L (2006) Treatment-resistant severe, active Graves&rsquo; ophthalmopathy successfully treated with B lymphocyte depletion. <i>Thyroid<\/i> 16: 709-710.","DOI":"10.1089\/thy.2006.16.709"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Khanna D, Chong KK, Afifiyan NF, Hwang CJ, Lee DK, et al. (2010) Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. <i>Ophthalmology<\/i> 117: 133-139.","DOI":"10.1016\/j.ophtha.2009.05.029"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Heemstra KA, Toes RE, Sepers J, Pereira AM, Corssmit EP, et al. (2008) Rituximab in relapsing Graves&rsquo; disease, a phase II study. <i>Eur J Endocrinol <\/i>159: 609-615.","DOI":"10.1530\/EJE-08-0084"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Heged&uuml;s L (2007) B lymphocyte depletion with the monoclonal antibody rituximab in Graves&rsquo; disease: a controlled pilot study. <i>J Clin Endocrinol Metab<\/i> 92: 1769-1772.","DOI":"10.1210\/jc.2006-2388"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hasselbalch HC (2003) B-cell depletion with rituximab-a targeted therapy for Graves&rsquo; disease and autoimmune thyroiditis. <i>Immunol Lett<\/i> 88: 85-86.","DOI":"10.1016\/S0165-2478(03)00032-4"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hashimoto K, Maruyama H, Nishiyama M, Asaba K, Ikeda Y, et al. (2005) Susceptibility alleles and haplotypes of human leukocyte antigen DRB1, DQA1, and DQB1 in autoimmune polyglandular syndrome type III in Japanese population. <i>Horm Res<\/i> 64: 253-260.","DOI":"10.1159\/000089293"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. El Fassi D, Banga JP, Gilbert JA, Padoa C, Heged&uuml;s L, et al. (2009) Treatment of Graves&rsquo; disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. <i>Clin Immunol<\/i> 130: 252-258.","DOI":"10.1016\/j.clim.2008.09.007"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Wang SH, Baker JR Jr (2006) Targeting B cells in Graves&rsquo; disease. <i>Endocrinology<\/i> 147: 4559-4560.","DOI":"10.1210\/en.2006-0852"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Miyauchi S, Matsuura B, Onji M (2000) Increased levels of serum interleukin-18 in Graves&rsquo; disease. <i>Thyroid<\/i> 10: 815-819.","DOI":"10.1089\/thy.2000.10.815"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Miyauchi S, Matsuura B, Ueda T, Eguchi T, Tamaru M, et al. (2013) Interleukin-18 induces insulin resistance in the hyperthyroid state. <i>Endocr J <\/i>60: 449-455.","DOI":"10.1507\/endocrj.EJ12-0136"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Keren Z, Braun-Moscovici Y, Markovits D, Rozin A, Nahir M, et al. (2009) Depletion of B lymphocytes in rheumatoid arthritis patients modifies IL-8-anti-IL-8 autoantibody network.<i> Clin Immunol<\/i> 133: 108-116.","DOI":"10.1016\/j.clim.2009.07.001"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Hauser SL, WaubantE, Arnold DL, Vollmer T, Antel J, et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. <i>N Engl J Med<\/i> 358: 676-688.","DOI":"10.1056\/NEJMoa0706383"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T13:37:44Z","timestamp":1650289064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/62\/1\/62_EJ14-0152\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej14-0152","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}